

Implementation of medium- and high-throughput automated solutions to meet the BTV testing challenge



Chantal Audeval,¹ Magali Ackermann,¹ Françoise Colocci,¹ Emmanuel Breard,² Corinne Sailleau,² Stephan Zientara,² Susanne Schlemm,³ Susanne Ullmann,³ and Laurent Thiery⁴

¹LDA 58, Nevers, France; ²AFSSA Maisons Alfort, France; ³QIAGEN GmbH, Hilden, Germany; ⁴QIAGEN S.A., Courtaboeuf CEDEX, France



Introduction

Bluetongue disease (BT), caused by the bluetongue virus serotype 8 (BTV-8), was unknown in the EU before 2006. After a major epidemic beginning in August 2006 in Netherlands, Belgium, Germany, Luxembourg, and the north of France, the disease spread across Europe and is currently present in the Spain, Italy, the Czech Republic, Denmark, and England. The disease has caused considerable socioeconomic concern and is an issue of major importance in the international trade of animals and animal products.

To minimize the risk of infected animals moving into disease-free areas, reliable diagnostic tools are essential. Since 2006, the French National Reference Laboratory (AFSSA, Maisons-Alfort) has been using a real-time reverse-transcription polymerase chain reaction (RT-PCR) assay for the rapid detection of BT virus in susceptible animals. The sensitivity and specificity of this "in-house" RT-PCR assay has been validated in a European inter-laboratory comparison for the detection of BT viral RNA. In 2007, the National Reference Laboratory decentralized this assay to allow diagnostics on a larger scale. Analyses from 3 sessions of inter-laboratory comparison demonstrated that the 58 participants provided satisfactory repeatability estimates and concordant status for all samples.


In addition to the assay, upstream extraction of RNA from complex samples such as whole blood must be established for different throughput needs. A number of RNA extraction methods have been validated and will be commercialized in France for diagnosis based on the real-time RT-PCR assay. Results are presented here for the development of an existing low-throughput manual procedure to establish standardized medium- and high-throughput procedures that require minimal human interactions using different automated systems.

Materials and methods

For medium-throughput processing (see flowchart, right), 100 µl whole blood from cattle was diluted with 40 µl PBS. RNA was extracted from 11 samples previously used for national ring test using the manual QIAamp[®] Viral RNA Mini Kit following the standard protocol (**Manual**) and in two runs of the automated QIAcube[®] "Body Fluid" protocol (**QIAcube**).


For high-throughput processing on the BioRobot[®] Universal System, 70 µl whole blood from cattle was processed using the QIAamp Virus BioRobot MDx Kit and a high-throughput, 96-well customized protocol available from QIAGEN (**BioRobot Universal**). Results are shown for 14 of the 103 samples prepared using several extraction conditions that gave acceptable results.

PCR was performed using the AFSSA protocol using a β-actin internal control. BTV viral RNA was detected with RT-PCR according to Toussaint *et al.*



Results for medium-throughput extraction

| Assay: | β-actin (internal control) | | | VP1 (target) | | | Result |
|---------------------|----------------------------|---------|--------|--------------|---------|--------|------------|
| | Manual | QIAcube | | Manual | QIAcube | | |
| Sample | | Test 1 | Test 2 | Test 1 | Test 2 | Test 2 | |
| 1 | 18.82 | 23.45 | 19.18 | 35.77 | 37.35 | 36.63 | Positive |
| 2 | 17.79 | 19.08 | 20.00 | 30.30 | 30.28 | 33.53 | Positive |
| 3 | 17.70 | 18.82 | 18.81 | 30.67 | 30.34 | 31.06 | Positive |
| 4 | 18.12 | 18.90 | 18.68 | 33.74 | 33.71 | 34.03 | Positive |
| 5 | 17.94 | 19.06 | 19.91 | 29.32 | 29.27 | 29.46 | Positive |
| 6 | 18.00 | 18.74 | 20.87 | ND | ND | ND | Negative |
| 7 | 17.50 | 18.87 | 20.95 | ND | ND | ND | Negative |
| 8 | 18.33 | 20.49 | 19.34 | 30.29 | 30.03 | 30.28 | Positive |
| 9 | 17.06 | 18.46 | 18.98 | 25.63 | 25.35 | 26.12 | Positive |
| 10 | 17.54 | 18.35 | 19.24 | 30.12 | 29.90 | 29.93 | Positive |
| 11 | 18.42 | 19.74 | 20.93 | 29.01 | 28.77 | 29.07 | Positive |
| Average | 17.93 | 19.45 | 19.72 | — | — | — | — |
| CV | 0.49 | 1.46 | 0.87 | — | — | — | — |
| Negative control | ND | ND | ND | ND | ND | ND | Control ok |
| No template control | ND | ND | ND | ND | ND | ND | Control ok |
| Positive control | ND | ND | ND | 21.02 | 20.88 | 21.17 | Control ok |
| Positive control | ND | ND | ND | 30.01 | 30.94 | 31.15 | Control ok |



The QIAcube.

ND: not detected.

Results for high-throughput extraction


| Assay: | β-actin (internal control) | | | VP1 (target) | | | Result |
|---------------------|----------------------------|----------|--------|--------------|----------|--------|------------|
| | Manual | BioRobot | | Manual | BioRobot | | |
| Sample | | Test 1 | Test 2 | Test 1 | Test 2 | Test 2 | |
| 19 | 20.77 | 20.89 | 21.20 | 27.87 | 26.57 | 27.11 | Positive |
| 184 | 19.57 | 19.75 | 20.04 | 33.25 | 33.82 | 32.58 | Positive |
| 197 | 19.21 | 20.58 | 20.68 | 31.76 | 31.28 | 30.74 | Positive |
| 198 | 19.5 | 21.89 | 22.28 | 34.43 | 34.05 | 35.00 | Positive |
| 203 | 19.34 | 21.48 | 22.23 | 32.8 | 32.31 | 32.60 | Positive |
| 204 | 19.46 | 20.91 | 21.38 | 33.72 | 32.21 | 32.36 | Positive |
| 208 | 19.01 | 21.79 | 22.51 | 39.14 | 38.23 | 39.39 | Positive |
| 220 | 19.09 | 21.26 | 21.04 | ND | ND | ND | Negative |
| 221 | 18.61 | 20.13 | 20.00 | ND | ND | ND | Negative |
| 222 | 19.24 | 21.21 | 21.46 | ND | ND | ND | Negative |
| 291 | 20.22 | 21.66 | 21.69 | 32.24 | 32.33 | 31.54 | Positive |
| 299 | 20.73 | 20.86 | 21.18 | 31.09 | 30.84 | 30.31 | Positive |
| 301 | 21.33 | 21.20 | 21.45 | 31.28 | 29.88 | 29.90 | Positive |
| 302 | 23.96 | 22.12 | 22.41 | 31.01 | 30.41 | 29.85 | Positive |
| Average | 20.00 | 21.12 | 21.40 | — | — | — | — |
| CV | 1.38 | 0.67 | 0.80 | — | — | — | — |
| Negative control | ND | ND | ND | ND | ND | ND | Control ok |
| No template control | ND | ND | ND | ND | ND | ND | Control ok |



The BioRobot Universal System.

ND: not detected.

Comparison of manual and automated extraction



No difference in sensitivity and specificity of the assay was observed. The implementation of different automated procedures increased the throughput capacity to approximately 470 samples/day and facilitated standardization and tracking of results. This method has been successfully transferred into routine workflows and provides the necessary flexibility for different throughput needs.

Discussion and Conclusions

Sample preparation is a critical step in detection of BT viral RNA by RT-PCR. We have established automated procedures for sample preparation and successfully implemented these procedures to manage testing during the BT outbreak in France. In the meantime, more than 14,000 blood samples have been processed successfully using the described automated sample preparation methods. The availability of 2 different throughput platforms based on the same purification technology provides testing laboratories reliable sample preparation with the necessary flexibility to meet changing throughput needs.

Acknowledgements
Anais CLERC, H el ene GUY, Bruno PERRAUDIN

References
Toussaint *et al.*, 2007. Bluetongue virus detection by two real time RT-qPCRs targeting two different genomic segments. *J. Virol. Methods* 140, 115

Trademarks: QIAGEN[®], QIAamp[®], QIAcube[®], BioRobot[®] (QIAGEN Group).
  2008 QIAGEN, all rights reserved.